DSGN Design Therapeutics Inc
Price (delayed)
$4.65
Market cap
$263.95M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.88
Enterprise value
$242.92M
Design Therapeutics is a biotechnology company developing a new class of therapies based on a platform of gene targeted chimera (GeneTAC™) small molecules. The company’s lead program is focused on
Highlights
DSGN's debt is down by 34% year-on-year and by 12% since the previous quarter
The EPS rose by 26% year-on-year but it has declined by 3.5% since the previous quarter
DSGN's net income is up by 26% YoY but it is down by 3.8% QoQ
The quick ratio has contracted by 15% from the previous quarter
Design Therapeutics's equity has decreased by 13% YoY and by 4.1% QoQ
Key stats
What are the main financial stats of DSGN
Market
Valuations
Earnings
Shares outstanding
56.76M
Market cap
$263.95M
Enterprise value
$242.92M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.09
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$62.38M
Net income
-$49.59M
EBIT
-$49.59M
EBITDA
-$48.99M
Free cash flow
-$43.45M
Per share
Balance sheet
Liquidity
EPS
-$0.88
EPS diluted
-$0.88
Free cash flow per share
-$0.77
Book value per share
$4.28
Revenue per share
$0
TBVPS
$4.45
Total assets
$252.09M
Total liabilities
$10M
Debt
$1.53M
Equity
$242.1M
Working capital
$239.58M
Debt to equity
0.01
Current ratio
29.31
Quick ratio
29.01
Net debt/EBITDA
0.43
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-18.7%
Return on equity
-19.3%
Return on invested capital
-21.7%
Return on capital employed
-20.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DSGN stock price
How has the Design Therapeutics stock price performed over time
Intraday
0.22%
1 week
-1.17%
1 month
-5.3%
1 year
42.64%
YTD
-24.64%
QTD
-24.64%
Financial performance
How have Design Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$62.38M
Net income
-$49.59M
Gross margin
N/A
Net margin
N/A
DSGN's net income is up by 26% YoY but it is down by 3.8% QoQ
DSGN's operating income is up by 20% year-on-year but it is down by 2.6% since the previous quarter
Growth
What is Design Therapeutics's growth rate over time
Valuation
What is Design Therapeutics stock price valuation
P/E
N/A
P/B
1.09
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS rose by 26% year-on-year but it has declined by 3.5% since the previous quarter
DSGN's P/B is 39% below its 5-year quarterly average of 1.8
Design Therapeutics's equity has decreased by 13% YoY and by 4.1% QoQ
Efficiency
How efficient is Design Therapeutics business performance
DSGN's ROE is up by 15% YoY but it is down by 7% QoQ
Design Therapeutics's ROA has increased by 14% YoY but it has decreased by 7% from the previous quarter
The company's return on invested capital rose by 12% YoY but it fell by 8% QoQ
Dividends
What is DSGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DSGN.
Financial health
How did Design Therapeutics financials performed over time
DSGN's total liabilities is down by 16% YoY but it is up by 9% QoQ
The quick ratio has contracted by 15% from the previous quarter
DSGN's debt is 99% smaller than its equity
DSGN's debt is down by 34% year-on-year and by 12% since the previous quarter
Design Therapeutics's equity has decreased by 13% YoY and by 4.1% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.